Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Signature Therapeutics Inc. Stories

2013-09-05 12:28:29

PALO ALTO, Calif., Sept. 5, 2013 /PRNewswire/ -- Signature Therapeutics, Inc., today presented four scientific posters at the PAINWeek 2013 national conference in Las Vegas. The posters illustrate the company's (i) trypsin-labile, immediate- and extended-release opioid prodrugs that release the parent opioid following oral administration; (ii) results of extended-release prodrugs oxycodone and hydromorphone withstanding tampering and abuse using standard crushing and extracting...

2013-07-29 16:25:15

PALO ALTO, Calif., July 29, 2013 /PRNewswire/ -- Signature Therapeutics, Inc., a development-stage biopharmaceutical company, announced today that it has received no-cost access to contractor resources through the National Center for Advancing Translational Sciences' Bridging Interventional Development Gaps (BrIDGs) program (part of the NIH) to support development of its extended-release, abuse-deterrent oxycodone, PF614 - a novel, inactive prodrug formulation that must be digested...

2013-07-12 12:25:51

WASHINGTON, July 12, 2013 /PRNewswire-USNewswire/ -- The Center for Lawful Access and Abuse Deterrence (CLAAD) praised Signature Therapeutics, Inc. today for taking a national lead in biopharmaceutical research and development to reduce prescription drug abuse. Signature Therapeutics is a privately held company developing next-generation abuse-deterrent prescription medications. More than 2.7 percent of the U.S. population currently abuses prescription drugs.[1] In 2010,...